ANGIODYNAMICS INC (ANGO): Results of Operations and Financial Condition
ANGIODYNAMICS INC (ANGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20077916_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability Delivered its seventh consecutive quarter of double-digit
How this was made
The 30-second read
Why it matters
Key decision inputs are the reported sales growth by segment (Med Tech vs Med Device), gross margin improvement, adjusted EBITDA and cash from operations, and incremental FDA IDE approvals plus a Medicare local coverage determination for NanoKnife effective July 5, 2026.
Market read
Traders can update near-term valuation models using the new Q4/FY financial datapoints and reimbursement/regulatory catalysts that may accelerate adoption in prostate and liver cancer indications.
What to watch
The excerpt emphasizes pro forma comparisons excluding divested/discontinued businesses; traders may need to assess underlying organic demand and margin sustainability beyond the mix shift and manufacturing transition.
Background
The 8-K (Item 2.02) is a primary disclosure of AngioDynamics’ Q4 and full-year FY2026 financial results and related clinical, regulatory, and market access updates.
Ticker impact
AngioDynamics reported FY2026 and Q4 results, including Med Tech net sales growth, adjusted EBITDA, and cash balance, plus FDA IDE and Medicare coverage updates.
Moderately positive bias for the next session as investors weigh record Q4/FY results, improving adjusted profitability, and incremental FDA IDE plus Medicare coverage for NanoKnife.
This is a primary 8-K earnings release with multiple concrete figures (sales, margins, adjusted EBITDA, cash) and specific clinical/regulatory milestones (FDA IDE approvals, Medicare local coverage determination effective July 5, 2026). However, the excerpt does not include full guidance or consensus context, limiting precision on magnitude.
Market effects
Supports the Med Tech and interventional oncology device read-through that reimbursement and incremental regulatory approvals can drive adoption and mix shift.
US-focused FDA IDE and Medicare coverage updates may influence US vascular/interventional oncology device peers’ reimbursement expectations.
Global market share and growth claims for cardiology and interventional oncology suggest competitive pressure in large, fast-growing markets, though details are company-specific.
Counterpoint
Despite record growth and positive adjusted EBITDA, the company still reported GAAP losses and faced tariff-related headwinds, so the market may discount durability of profitability.
Key entities
- companyAngioDynamics, Inc.
NASDAQ-listed medical technology company reporting FY2026 and Q4 results and multiple FDA IDE and Medicare coverage milestones.
- productNanoKnife
Irreversible electroporation platform referenced with two-year PRESERVE follow-up data and Medicare local coverage determination effective July 5, 2026.
- productAlphaVac and AngioVac
Mechanical thrombectomy platform components referenced with FDA IDE approvals for AlphaReturn and PAVE studies.
